Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2013 1
2015 2
2017 3
2018 1
2019 6
2020 9
2021 8
2022 12
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: ENSG00000183723
Page 1
CMTM4 is a subunit of the IL-17 receptor and mediates autoimmune pathology.
Knizkova D, Pribikova M, Draberova H, Semberova T, Trivic T, Synackova A, Ujevic A, Stefanovic J, Drobek A, Huranova M, Niederlova V, Tsyklauri O, Neuwirth A, Tureckova J, Stepanek O, Draber P. Knizkova D, et al. Nat Immunol. 2022 Nov;23(11):1644-1652. doi: 10.1038/s41590-022-01325-9. Epub 2022 Oct 21. Nat Immunol. 2022. PMID: 36271145 Free PMC article.
Both mouse and human cell lines deficient in CMTM4 were largely unresponsive to IL-17A, due to their inability to assemble the IL-17R signaling complex. ...Collectively, our data identified CMTM4 as an essential component of IL-17R and a potential therapeutic target …
Both mouse and human cell lines deficient in CMTM4 were largely unresponsive to IL-17A, due to their inability to assemble the IL-17R …
Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, Zhang Z, Xu K, Duan J, He S, Zhang J, Wan L, Liu T, Zhou X, Hung MC, Freeman GJ, Wei W. Dai X, et al. Mol Cell. 2021 Jun 3;81(11):2317-2331.e6. doi: 10.1016/j.molcel.2021.03.037. Epub 2021 Apr 27. Mol Cell. 2021. PMID: 33909988 Free PMC article.
Mechanistically, energy deprivation activates AMP-activated protein kinase (AMPK), which in turn, phosphorylates PD-L1 on Ser283, thereby disrupting its interaction with CMTM4 and subsequently triggering PD-L1 degradation. In addition, AMPK phosphorylates EZH2, which disru …
Mechanistically, energy deprivation activates AMP-activated protein kinase (AMPK), which in turn, phosphorylates PD-L1 on Ser283, thereby di …
MARVEL domain containing CMTM4 affects CXCR4 trafficking.
Bona A, Seifert M, Thünauer R, Zodel K, Frew IJ, Römer W, Walz G, Yakulov TA. Bona A, et al. Mol Biol Cell. 2022 Nov 1;33(13):ar116. doi: 10.1091/mbc.E22-05-0152. Epub 2022 Aug 31. Mol Biol Cell. 2022. PMID: 36044337 Free PMC article.
The MARVEL proteins CMTM4 and CMTM6 control PD-L1, thereby influencing tumor immunity. ...Furthermore, we observed that cmtm4 depletion promotes the separation of cells from the pLLP cell cluster in zebrafish embryos. ...
The MARVEL proteins CMTM4 and CMTM6 control PD-L1, thereby influencing tumor immunity. ...Furthermore, we observed that cmtm4 …
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM. Mezzadra R, et al. Nature. 2017 Sep 7;549(7670):106-110. doi: 10.1038/nature23669. Epub 2017 Aug 16. Nature. 2017. PMID: 28813410 Free PMC article.
Furthermore, through both a haploid genetic modifier screen in CMTM6-deficient cells and genetic complementation experiments, we demonstrate that this function is shared by its closest family member, CMTM4, but not by any of the other CMTM members tested. Notably, CMTM6 in …
Furthermore, through both a haploid genetic modifier screen in CMTM6-deficient cells and genetic complementation experiments, we demonstrate …
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, Yang Z, Sator-Schmitt M, Engel H, Li X, Broderick C, Jin G, Gomez-Eerland R, Rozeman L, Lei X, Matsuo H, Yang C, Hofland I, Peters D, Broeks A, Laport E, Fitz A, Zhao X, Mahmoud MAA, Ma X, Sander S, Liu HK, Cui G, Gan Y, Wu W, Xiao Y, Heck AJR, Guan W, Lowe SW, Horlings HM, Wang C, Brummelkamp TR, Blank CU, Schumacher TNM, Sun C. Miao B, et al. Cancer Cell. 2023 Oct 9;41(10):1817-1828.e9. doi: 10.1016/j.ccell.2023.08.008. Epub 2023 Sep 7. Cancer Cell. 2023. PMID: 37683639 Free article.
CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
Zhang T, Yu H, Dai X, Zhang X. Zhang T, et al. Front Immunol. 2022 Jul 25;13:971428. doi: 10.3389/fimmu.2022.971428. eCollection 2022. Front Immunol. 2022. PMID: 35958549 Free PMC article. Review.
The roles of CMTM6 and CMTM4 in regulating TME components, including immune cells and tumor cells themselves were discussed in this review. The potential clinical applications of CMTM6 and CMTM4 as biomarkers to predict therapy efficacy and as new or combined immuno …
The roles of CMTM6 and CMTM4 in regulating TME components, including immune cells and tumor cells themselves were discussed in this r …
CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma.
Li H, Liu YT, Chen L, Zhou JJ, Chen DR, Li SJ, Sun ZJ. Li H, et al. Mol Carcinog. 2021 Aug;60(8):556-566. doi: 10.1002/mc.23323. Epub 2021 Jun 1. Mol Carcinog. 2021. PMID: 34061408
Moreover, knockdown of CMTM4 decreased CSC-associated markers via the protein kinase B pathway. Notably, CMTM4-knockdown inhibited the expression of interferon-gamma induced PD-L1 in HNSCC cells. ...
Moreover, knockdown of CMTM4 decreased CSC-associated markers via the protein kinase B pathway. Notably, CMTM4-knockdown inhib …
Expression of CMTM4 shows clinical significance in lung cancer.
Zhu X, Zhang S, Tan S, Li D, Chen X, Kong J, Fu Y, Wang C, Wen L. Zhu X, et al. Transl Cancer Res. 2020 Oct;9(10):6214-6220. doi: 10.21037/tcr-20-1254. Transl Cancer Res. 2020. PMID: 35117232 Free PMC article.
Moreover, lung cancer patients with negative expression of CMTM4 had a shorter survival time than the patients with positive expression of CMTM4. ...CONCLUSIONS: Our study supports that CMTM4 can be used as a new marker for the treatment and prognosis of lung …
Moreover, lung cancer patients with negative expression of CMTM4 had a shorter survival time than the patients with positive expressi …
The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM, Abuharfeil NM, Darmani H. Yaseen MM, et al. Clin Transl Oncol. 2022 Aug;24(8):1478-1491. doi: 10.1007/s12094-022-02811-0. Epub 2022 Mar 12. Clin Transl Oncol. 2022. PMID: 35278198 Review.
The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family, as master positive regulators of PD-L1 expression, the primary ligand of programmed cell death 1 (PD-1), on tumor …
The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane …
CMTM4 makes IL-17 signaling more complex.
Foley JF. Foley JF. Sci Signal. 2022 Nov 29;15(762):eadf9180. doi: 10.1126/scisignal.adf9180. Epub 2022 Nov 29. Sci Signal. 2022. PMID: 36445938
49 results